vs
Side-by-side financial comparison of Community West Bancshares (CWBC) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Vanda Pharmaceuticals Inc. is the larger business by last-quarter revenue ($57.2M vs $38.3M, roughly 1.5× Community West Bancshares). On growth, Community West Bancshares posted the faster year-over-year revenue change (11.6% vs 7.6%). Community West Bancshares produced more free cash flow last quarter ($43.6M vs $-29.5M). Over the past eight quarters, Community West Bancshares's revenue compounded faster (36.0% CAGR vs 9.8%).
Community West BancsharesCWBCEarnings & Financial Report
Community West Bancshares is a registered bank holding company headquartered in California. It wholly owns Community West Bank under the Bank Holding Company Act.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
CWBC vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $57.2M |
| Net Profit | — | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | 40.0% | -70.5% |
| Net Margin | — | -246.8% |
| Revenue YoY | 11.6% | 7.6% |
| Net Profit YoY | — | -2774.3% |
| EPS (diluted) | $0.58 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $57.2M | ||
| Q3 25 | $37.9M | $56.3M | ||
| Q2 25 | $35.7M | $52.6M | ||
| Q1 25 | $34.8M | $50.0M | ||
| Q4 24 | $34.3M | $53.2M | ||
| Q3 24 | $31.3M | $47.7M | ||
| Q2 24 | $30.5M | $50.5M | ||
| Q1 24 | $20.7M | $47.5M |
| Q4 25 | — | $-141.2M | ||
| Q3 25 | $10.9M | $-22.6M | ||
| Q2 25 | $7.8M | $-27.2M | ||
| Q1 25 | $8.3M | $-29.5M | ||
| Q4 24 | — | $-4.9M | ||
| Q3 24 | $3.4M | $-5.3M | ||
| Q2 24 | $-6.3M | $-4.5M | ||
| Q1 24 | $3.7M | $-4.1M |
| Q4 25 | 40.0% | -70.5% | ||
| Q3 25 | 39.8% | -55.6% | ||
| Q2 25 | 30.2% | -73.2% | ||
| Q1 25 | 32.7% | -82.0% | ||
| Q4 24 | 31.0% | -19.3% | ||
| Q3 24 | 13.3% | -23.1% | ||
| Q2 24 | -25.9% | -20.1% | ||
| Q1 24 | 23.2% | -19.5% |
| Q4 25 | — | -246.8% | ||
| Q3 25 | 28.7% | -40.1% | ||
| Q2 25 | 22.0% | -51.7% | ||
| Q1 25 | 23.8% | -58.9% | ||
| Q4 24 | — | -9.2% | ||
| Q3 24 | 10.8% | -11.2% | ||
| Q2 24 | -20.7% | -9.0% | ||
| Q1 24 | 17.8% | -8.7% |
| Q4 25 | $0.58 | $-2.40 | ||
| Q3 25 | $0.57 | $-0.38 | ||
| Q2 25 | $0.41 | $-0.46 | ||
| Q1 25 | $0.44 | $-0.50 | ||
| Q4 24 | $0.29 | $-0.09 | ||
| Q3 24 | $0.18 | $-0.09 | ||
| Q2 24 | $-0.33 | $-0.08 | ||
| Q1 24 | $0.31 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $119.0M | $84.9M |
| Total DebtLower is stronger | $69.5M | — |
| Stockholders' EquityBook value | $409.6M | $327.2M |
| Total Assets | $3.7B | $488.9M |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $119.0M | $84.9M | ||
| Q3 25 | $121.6M | $70.0M | ||
| Q2 25 | $134.4M | $81.0M | ||
| Q1 25 | $148.4M | $111.8M | ||
| Q4 24 | $120.4M | $102.3M | ||
| Q3 24 | $149.0M | $100.5M | ||
| Q2 24 | $109.7M | $103.0M | ||
| Q1 24 | $61.0M | $125.2M |
| Q4 25 | $69.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $69.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $409.6M | $327.2M | ||
| Q3 25 | $397.6M | $466.0M | ||
| Q2 25 | $380.0M | $486.3M | ||
| Q1 25 | $372.2M | $511.4M | ||
| Q4 24 | $362.7M | $538.5M | ||
| Q3 24 | $363.5M | $541.2M | ||
| Q2 24 | $350.2M | $542.5M | ||
| Q1 24 | $211.7M | $544.0M |
| Q4 25 | $3.7B | $488.9M | ||
| Q3 25 | $3.6B | $601.1M | ||
| Q2 25 | $3.6B | $624.7M | ||
| Q1 25 | $3.6B | $631.9M | ||
| Q4 24 | $3.5B | $656.2M | ||
| Q3 24 | $3.5B | $645.1M | ||
| Q2 24 | $3.5B | $651.4M | ||
| Q1 24 | $2.4B | $652.7M |
| Q4 25 | 0.17× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.1M | $-29.4M |
| Free Cash FlowOCF − Capex | $43.6M | $-29.5M |
| FCF MarginFCF / Revenue | 113.9% | -51.6% |
| Capex IntensityCapex / Revenue | 6.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $77.7M | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.1M | $-29.4M | ||
| Q3 25 | $13.2M | $-31.6M | ||
| Q2 25 | $11.5M | $-15.3M | ||
| Q1 25 | $11.1M | $-33.1M | ||
| Q4 24 | $22.2M | $-1.8M | ||
| Q3 24 | $7.8M | $-14.6M | ||
| Q2 24 | $5.2M | $-6.9M | ||
| Q1 24 | $4.0M | $7.6M |
| Q4 25 | $43.6M | $-29.5M | ||
| Q3 25 | $12.8M | $-31.8M | ||
| Q2 25 | $10.6M | $-15.6M | ||
| Q1 25 | $10.8M | $-33.6M | ||
| Q4 24 | $17.2M | $-2.0M | ||
| Q3 24 | $5.2M | $-14.7M | ||
| Q2 24 | $4.8M | $-7.0M | ||
| Q1 24 | $3.6M | $7.6M |
| Q4 25 | 113.9% | -51.6% | ||
| Q3 25 | 33.7% | -56.5% | ||
| Q2 25 | 29.6% | -29.6% | ||
| Q1 25 | 30.9% | -67.1% | ||
| Q4 24 | 50.0% | -3.8% | ||
| Q3 24 | 16.7% | -30.9% | ||
| Q2 24 | 15.7% | -13.9% | ||
| Q1 24 | 17.3% | 15.9% |
| Q4 25 | 6.6% | 0.2% | ||
| Q3 25 | 1.1% | 0.3% | ||
| Q2 25 | 2.7% | 0.6% | ||
| Q1 25 | 0.9% | 0.9% | ||
| Q4 24 | 14.7% | 0.4% | ||
| Q3 24 | 8.1% | 0.3% | ||
| Q2 24 | 1.4% | 0.2% | ||
| Q1 24 | 2.1% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWBC
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
